Home>Topics>Stocks>Savient Pharmaceuticals

Savient Pharmaceuticals SVNT

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Savient Pharmaceuticals files for Chapter 11 bankruptcy

      Headlines

      Mon, 14 Oct 2013

      Oct 14 (Reuters) - U.S. biotech firm Savient Pharmaceuticals Inc filed for Chapter 11 bankruptcy protection in a Delaware court on Monday and said it has agreed to sell most of its assets to Sloan...

    2. Dropping Coverage of Savient After Another Disappointing Quarter

      Commentary

      Tue, 19 Mar 2013

      Savient SVNT (rating: CC) reported another quarter of disappointing results, and we plan to drop equity and credit coverage of the name

    3. New Morningstar Analyst Report for Savient Pharmaceuticals

      Stock Reports

      Tue, 8 Jan 2013

      Despite numerous setbacks and poor execution, Savient still has a strong product.

    4. Krystexxa Launch Remains Slow but Steady as Savient Waits for European Approval

      Commentary

      Thu, 8 Nov 2012

      Savient Pharmaceuticals SVNT reported third-quarter results that were largely in line with our expectations. Krystexxa remains on the slow-but-steady

    5. Savient's Krystexxa Launch Still Slow, but Showing Signs of Improvement

      Commentary

      Wed, 8 Aug 2012

      Savient SVNT reported second-quarter Krystexxa sales that were largely in line with expectations and we do not plan to change our fair value

    6. Savient to cut jobs, names new CEO

      Headlines

      Mon, 9 Jul 2012

      (Reuters) - Savient Pharmaceuticals Inc said it would cut about 35 percent of its workforce and named a new chief executive as it struggles to stay afloat amid weak sales of its chronic gout drug...

    7. Savient Appoints CEO, Initiates Cost-Cutting Plans

      Commentary

      Mon, 9 Jul 2012

      Savient Pharmaceuticals SVNT announced that Louis Ferrari, executive vice president and president of North American commercial operations, has been appointed

    8. Savient's loss widens, shares fall

      Headlines

      Wed, 9 May 2012

      (Reuters) - Savient Pharmaceuticals Inc posted a wider-than-expected loss on weak sales of its gout drug Krystexxa in the first two months, sending its shares down 13 percent.

    9. Krystexxa 1Q Sales Disappoint; We Plan to Lower Our Fair Value Estimate for Savient

      Commentary

      Wed, 9 May 2012

      Savient SVNT reported weaker-than-expected first-quarter Krystexxa sales, and we plan to lower our fair value estimate to $1.50 from

    10. UPDATE 1-Savient says court denies creditor's injunction request

      Headlines

      Tue, 8 May 2012

      May 8 (Reuters) - Savient Pharmaceuticals Inc said a Delaware court denied a request for an injunction by its largest creditor, Tang Capital Partners, to halt Savient's plan to raise about $44...

    « Prev123Next »
    Content Partners